Table 1.
Demographic and clinical characteristics of the participants according to SUI status
| Patients with SUI (n = 47) |
Patients without SUI (n = 36) |
p value | Cohen’s d (95% Cl) | |
|---|---|---|---|---|
| Age, years | 67.8 ± 4.7 | 66.3 ± 5.7 | 0.20 | 0.29(-0.15 to 0.73) |
| BMI, kg/m2 | 26.9 ± 2.8 | 27.6 ± 4.2 | 0.33 |
-0.20 (-0.64 to 0.23) |
| Comorbidity | 0.46 | |||
| DM | 6(12.8) | 5(13.9) | ||
| HT | 15(31.9) | 18(50) | ||
| Hypothyroidism | 1(2.1) | 3(8.3) | ||
| CAD | 1(2.1) | 5(13.9) | ||
| Asthma | 2(4.3) | 1(2.8) | ||
| DXA T-score | ||||
| Lumbar Spine T-score | -2.8 ± 0.6 | -2.7 ± 0.9 | 0.49 |
-0.13 (-0.57 to 0.30) |
| Femur Neck T-score | -1.2 ± 0.8 | -1.3 ± 1.0 | 0.77 |
0.11 (-0.32 to 0.55) |
| Current osteoporosis treatment | 0.72 | |||
| Bisphosphonate + cholecalciferol | 43(91.5) | 32(88.9) | ||
| Alendronate + cholecalciferol | 21(44.6) | 14(38.8) | ||
| Ibandronate + cholecalciferol | 17(36.1) | 9(25) | ||
| Zoledronic acid + cholecalciferol | 5(10.6) | 8(22.2) | ||
| Denosumab + cholecalciferol | 4(8.5) | 4(11.1) | ||
| HADS-A | 7.7 ± 4.6 | 6.1 ± 4.0 | 0.08 |
0.37 (-0.07 to 0.81) |
| HADS-D | 9.2 ± 4.6 | 6.3 ± 3.8 | 0.004 |
0.68 (0.23 to 1.13) |
Abbreviations: BMI Body mass index, DM Diabetes mellitus, HT Hypertension, CAD Coronary artery disease, DXA Dual-energy X-ray absorptiometry, HADS-A Hospital anxiety and depression scale anxiety score, HADS-D Hospital anxiety and depression scale depression score, SUI Stress urinary incontinence